ContributorsPublishersAdvertisers

Promising Efficacy and Safety Profile Seen With Concurrent Ibrutinib and Venetoclax for R/R Mantle Cell Lymphoma

cancernetwork.com
 2021-11-19

Cover picture for the articlePhase 3 data suggest that concurrent treatment with ibrutinib and venetoclax yielded promising efficacy for patients with relapsed/refractory mantle cell lymphoma. A concurrent combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) yielded promising efficacy with no new safety signals in a population of patients with relapsed/refractory mantle cell lymphoma (MCL), according to...

www.cancernetwork.com

Comments / 0

Comments / 0